Parametric Portfolio Associates’s Krystal Biotech KRYS Stock Holding History

Parametric Portfolio Associates’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$2.47M	Sell	37,070 -2,377	-6%	-$148K	﹤0.01%	2311
2021 Q4	$2.76M	Buy	39,447 +33,525	+566%	+$1.95M	﹤0.01%	2247
2021 Q3	$309K	Sell	5,922 -1,579	-21%	-$93.5K	﹤0.01%	3294
2021 Q2	$510K	Buy	7,501 +388	+5%	+$27.1K	﹤0.01%	3079
2021 Q1	$548K	Buy	+7,113	New	+$517K	﹤0.01%	3458
2020 Q4	–	Sell	-5,083	Closed	-$219K	–	4012
2020 Q3	$219K	Buy	+5,083	New	+$221K	﹤0.01%	3619
2020 Q2	–	Sell	-18,849	Closed	-$815K	–	3970
2020 Q1	$815K	Sell	18,849 -2,823	-13%	-$148K	﹤0.01%	2910
2019 Q4	$1.2M	Sell	21,672 -4,041	-16%	-$198K	﹤0.01%	2964
2019 Q3	$893K	Sell	25,713 -4,621	-15%	-$207K	﹤0.01%	3082
2019 Q2	$1.22M	Buy	+30,334	New	+$992K	﹤0.01%	2953

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Parametric Portfolio Associates's KRYS Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Krystal Biotech (KRYS) stake by 6% in Q1 2022, selling an estimated $148K and leaving 37,070 shares worth $2.47M. The position accounts for ﹤0.01% of the portfolio, ranked #2311.

Parametric Portfolio Associates first reported a position in KRYS in Q2 2019 and has held it in 10 quarters since. The position peaked at $2.76M in Q4 2021. 135 funds tracked by Wall St. Rank hold KRYS as of Q1 2022.

Parametric Portfolio Associates held 37,070 shares of Krystal Biotech worth $2.47M as of Q1 2022.
Parametric Portfolio Associates sold 2,377 Krystal Biotech shares in Q1 2022, an estimated $148K.
Krystal Biotech made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2311 holding.
Parametric Portfolio Associates first reported a position in Krystal Biotech in Q2 2019 and has held it in 10 quarters since.
Parametric Portfolio Associates's Krystal Biotech position peaked at $2.76M in Q4 2021.
135 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.